The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603).
 
Kohei Shitara
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Novartis; Novartis; Novartis; Novartis; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Takeda; Takeda; Takeda; Takeda
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroki Hara
No Relationships to Disclose
 
Naoki Takahashi
No Relationships to Disclose
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma
Research Funding - Astellas Amgen BioPharama (Inst); Astellas Amgen BioPharama (Inst); Astellas Amgen BioPharama (Inst); Astellas Amgen BioPharama (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst)
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Masako Asayama
No Relationships to Disclose
 
Takako Yoshii
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Takeda; Takeda; Takeda; Takeda
Consulting or Advisory Role - Merck Serono; Merck Serono; Merck Serono; Merck Serono
 
Hitomi Tamura
No Relationships to Disclose
 
Yuichi Mikamoto
No Relationships to Disclose
 
Nami Hirano
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
 
Shogo Nomura
Employment - Asahi Kasei (I); Asahi Kasei (I); Asahi Kasei (I); Asahi Kasei (I)
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Pfizer; Pfizer; Pfizer; Pfizer; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Akihiro Sato
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices; Pentax Medical Devices; Pentax Medical Devices; Pentax Medical Devices; Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Hiroyoshi Nishikawa
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Celgene; Celgene; Celgene; Celgene; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Eisai; Eisai; Eisai; Eisai; MSD K.K; MSD K.K; MSD K.K; MSD K.K; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BD Biosciences; BD Biosciences; BD Biosciences; BD Biosciences; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; KYOWA HAKKO BIO; KYOWA HAKKO BIO; KYOWA HAKKO BIO; KYOWA HAKKO BIO; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sysmex; Sysmex; Sysmex; Sysmex; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Zenyaku Kogyo; Zenyaku Kogyo; Zenyaku Kogyo; Zenyaku Kogyo
 
Shota Fukuoka
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst)